title: [Clinical evaluation of panipenem/betamipron in children].
abstract: Panipenem/betamipron (PAPM/BP), a new injectable carbapenem antibiotic, was evaluated for its safety and efficacy in children. Ninety three percentage (14 in 15 cases) of various infections were cured with PAPM/BP therapy. Transient skin rash occurred in 1 case, probably due to the histamine-like effect of PAPM/BP. The plasma half life of panipenem was 0.85 +/- 0.07 hours. PAPM/BP was evaluated to be a less-epileptogenic carbapenem antibiotic.
authors.affiliation: Department of Pediatrics, Ichihara Hospital, Teikyo University School of Medicine.
authors.forename: H
authors.initials: H
authors.lastname: Meguro
authors.forename: A
authors.initials: A
authors.lastname: Mori
authors.forename: R
authors.initials: R
authors.lastname: Fujii
authors.forename: I
authors.initials: I
authors.lastname: Terashima
mesh_terms: D001424:Bacterial Infections / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D004359:Drug Therapy, Combination / Q000097:blood / Q000627:therapeutic use; D005069:Evaluation Studies as Topic; D005260:Female; D006207:Half-Life; D006801:Humans; D007223:Infant; D008297:Male; D013845:Thienamycins / Q000097:blood / Q000627:therapeutic use*; D015091:beta-Alanine / Q000031:analogs & derivatives* / Q000097:blood / Q000627:therapeutic use
chemical_list: D013845:Thienamycins; D015091:beta-Alanine; C075316:panipenem-betamipron